What is the latest market price of a box of Selumetinib?

Selumetinib(Selumetinib) is a selective MEK1/2 inhibitor and a precision targeted therapy drug. It is mainly used to treat patients with neurofibromatosis type 1 (Neurofibromatosis type 1) associated with NF1 gene mutations, especially for unresectable neurofibromas in children and adolescents. It has important clinical significance. This drug blocks abnormal cell proliferation from the source by inhibiting the RAS/MAPK signaling pathway, thereby inhibiting the continued growth of tumors, reducing pain and nerve compression, and improving quality of life.

Compared with traditional surgery or radiotherapy, selumetinib is a non-invasive treatment method. Patients can maintain long-term efficacy by taking it orally, and it has more advantages for patients with deep neural tissue or multiple lesions. In addition, some studies have shown that selumetinib can improve the texture of tumors to a certain extent, make them softer, and reduce movement disorders or appearance deformities caused by local compression, which has positive significance for the growth and development of children.

In terms of price, the original drug of selumetinib has been officially launched in China and has been included in the medical insurance reimbursement catalog, which has reduced the financial burden on patients. Common specifications currently on the market include10mg 60 capsules and 25mg 60 capsules. The domestic price of each box is about 20,000 yuan. If the medical insurance reimbursement policy is followed, the actual payment may be lower. In overseas markets, the price of European original drugs is higher. For example, the price of 10mg*60 capsules may exceed RMB 50,000. The price difference is mainly affected by exchange rates and market policies.

At the same time, some countries and regions have launched generic versions. For example, selumetinib produced by Lucius Pharmaceuticals in Laos has the same specifications as the original drug. The price per box is about between 1,000 and more than 2,000 yuan. The ingredients of the drug are consistent with the original drug. However, due to different production standards and approval mechanisms, clinical application still needs to follow the guidance of doctors.

Overall, the emergence of selumetinib provides new treatment hope forNF1-related neurofibromas. Its precise mechanism of action and good oral compliance make it one of the important representatives in the field of targeted therapy today.

Reference materials:https://www.koselugo.com